Light Mode
$87.80 ↓ -1.88 (-2.09%) Trading Down from the previous close of $89.67, $2.07 below the day’s high of $89.86
-15.89 (-15.05%) / 6M
Momentum, market sentiment, and recent alerts
BNTX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -14.4%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.